Insight | Peptides like BPC-157: promising science, thin evidence, real risks

The Short Version

Peptides such as BPC-157, TB-500 and the growth-hormone-releasing peptides are exciting, but the excitement runs well ahead of the human evidence. Dr. Craig Koniver, a physician who has prescribed peptides for about eight years, reports thousands of patients who became less stiff and sore on BPC-157 and describes the growth hormone peptides as tools with distinct, useful "flavors [1]. Andrew Huberman, reviewing the same compounds on his own, points out that almost all of the data come from rats and mice, that he knows of only one poorly performed human study on BPC-157, and that the same growth signals that speed healing could, in theory, feed a tumor [2][3]. Both men agree on the guardrails: see a board-certified physician, use compounding-pharmacy sources rather than research only" products, start with the minimum effective dose, cycle off, and monitor your health [1][2]. Anyone tempted by peptide hype should see these as potent, early-stage drugs, not harmless supplements.

What They Said

Where peptides fit, and why they appeal

Dr. Koniver's definition is plain: peptides are just chains of amino acids [1]. In his framing, a chain of 40 amino acids or fewer is a peptide and 41 or more is a protein; the body makes around 300,000 peptides by the last count he read, and clinicians have used perhaps 150 of them therapeutically, so he considers the field still early [1]. Huberman draws the line a little differently, at 2 to 50 amino acids, while noting that chains of 75 or 100 are often still called peptides, and he pictures them as beads on a string whose order decides what the peptide does [2]. Familiar examples include insulin and oxytocin [1][2].

Huberman places peptides on a ladder. At the bottom is diet and exercise, then supplements, then prescription hormone therapies such as testosterone and growth hormone. Peptides, he says, "sit somewhere between doing nothing, except diet and exercise, supplements" and the full hormone therapies, which "can shut down one's natural production of those hormone pathways" [1]. The appeal is that a peptide can push on a specific pathway, such as growth hormone release, without the negative feedback that follows taking the hormone itself [1].

Dr. Koniver builds his whole practice on that idea. "I don't ever want to manipulate hormones," he says, meaning he doesn't want to give people more than they would get in nature [1]. That is why he dislikes testosterone pellets: "you're exposing people to a concentration of hormones we would never ever see in nature" [1]. With peptides, he says, "I want to just stick within kind of the highways of the lane, swim lanes for how they should operate and then take advantage of that" [1].

Dr. Koniver's clinical case for BPC-157

BPC-157 (body protection compound 157) has been Dr. Koniver's most-used peptide, given to almost every patient for its anti-inflammatory effect [1]. He has seen thousands of patients become less stiff and sore, with improvements in knees and shoulders, and says it helped with recovery after viral illness [1]. His clinic started at 500 micrograms a day and went as high as 5,000, typically five days on and two days off [1].

On route of delivery, he notes that BPC-157 is unusual. Huberman observes: "It's a gut peptide. So we don't have to worry about it being destroyed by the gut" [1]. Most peptides are broken down in digestion, but this one occurs naturally in the gut and survives there [1]. Even so, Dr. Koniver found oral forms less useful: "What we've observed is more limited to the gut," helping people with Crohn's, colitis or irritable bowel [1]. Injections under the skin, with a tiny insulin-style needle he says hurts less than a mosquito bite, worked better, even for gut problems, and seemed to act throughout the body no matter where they were given [1].

Huberman is struck that a small injection near the belly button could help an injured elbow. Dr. Koniver compares it to a study in which tagged intravenous stem cells gathered at a wrist fracture within 24 hours [1]. He says BPC-157 shines for tendons and ligaments and can even be injected directly into tendons mixed with PRP or PRF, something he says you would never do with steroids; IV doses served as a quick "spark, followed by injections under the skin [1]. He also reports that BPC-157 appears to upregulate growth hormone receptors, so it pairs well with growth-hormone-releasing peptides: Then you can use less of the growth hormone releasing peptide with the same result" [1].

He reports no notable side effects with BPC-157 or its replacement [1]. That replacement exists because in October 2023 the FDA placed BPC-157 and many other peptides on a list that bars compounding pharmacies from making them [1]. His alternative is pentadeca arginate (PDA), which differs from BPC-157 by one amino acid and, early on, produces very similar results; he starts at 250 to 500 micrograms injected daily, Monday to Friday, a dose he calls conservative [1].

Huberman's case for caution on BPC-157

In his solo episode, Huberman explains why a gut peptide might heal other tissues. The gut lining constantly replaces its cells, and that turnover is essentially the same process as wound repair; neurons, by contrast, are largely fixed after about age 25 [2]. He adds a grim historical note: surgeons sometimes placed severed fingers or hands inside a patient's abdomen to keep them alive until reattachment, which fed the idea that something in the gut preserves tissue [2].

The animal mechanism is striking. In animal studies BPC-157 promotes angiogenesis, the growth of new blood vessels, at injury sites, partly through the endothelial nitric oxide pathway, and draws fibroblasts into the injury to build a strong scaffold for repair [2]. Rat studies on sciatic nerve and Achilles tendon injuries, including complete transections, show impressive results [2]. The injury itself seems to signal where BPC-157 should act, though how it travels there is not understood, and the anecdotal data suggest injecting a few inches from the belly button works about as well as injecting near the injury [2]. That matches Dr. Koniver's clinical observation [1].

Then comes the gap. Rigorous animal research dates back to about 1993, but Huberman knows of only one human study, which he calls poorly performed and not a clinical trial, even though hundreds of thousands or perhaps millions of people now take BPC-157 [2]. Without controlled trials, placebo effects can't be ruled out [2]. In animals the LD50 is very high, around two grams per kilogram of body weight, but he stresses that this does not mean anyone should take high doses [2].

His most serious warning is one he says is rarely discussed. BPC-157 slightly raises growth hormone receptors and increases VEGF (vascular endothelial growth factor) to drive new blood vessels, and tumors thrive on blood flow and growth factors [2]. Avastin, a common cancer drug, works by blocking VEGF, the exact opposite effect [2]. His conclusion: "BPC 157 is a potential tumor growth risk," and anyone with a known cancer or concerns about tumors should be very cautious; eye diseases involving vascular overgrowth are another reason for caution [2]. Recovering faster to train or play sports is attractive, he says, but not at the cost of growing or accelerating a cancer [2].

TB-500 and the thymus peptides

Only Huberman's solo episode covers thymosin beta-4 and its shortened synthetic version, TB-500, which lasts somewhat longer [2]. Thymosin beta-4 is made by the thymus, a gland present in children that disappears with age. Because children heal faster and with less scarring, researchers wondered whether thymus peptides contribute, a link Huberman stresses is only correlational [2]. Mechanistically, it promotes the growth and infiltration of many cell types involved in healing, including stem cell proliferation and growth of the extracellular matrix, and it is often taken alongside BPC-157 [2]. He corrects a common belief: as far as he knows, TB-500 does not act on the growth hormone pathway; it is about repair [2]. Again, the evidence is mostly from mice and rats, and people's reports of faster healing have no control comparison [2].

A related thymus peptide shows how quickly the rules move. Dr. Koniver calls thymosin alpha-1 the best peptide for immune modulation, useful in autoimmune disease and long COVID at about 5,000 micrograms a day, and at the time of recording it had been removed [1]. In a late update, Huberman reports that three peptides, CJC-1295, ipamorelin and a thymosin peptide, had been "reallowed for prescription in the United States" [1].

Growth hormone peptides: Dr. Koniver's "flavors"

These peptides stimulate the body's own growth hormone rather than supplying it. As Huberman puts it, "This is not taking growth hormone" [1]. Dr. Koniver walks through the pathway: ipamorelin, injected under the skin, prompts the pituitary to release growth hormone, which travels to the liver to make IGF-1, "which then enters the circulation is very anabolic, meaning growth, healing, mending" [1]. As we age we make less growth hormone and wear down, and the peptide lets you both push out a little more and direct when it happens [1].

Timing matters to him. Because the largest growth hormone pulse is thought to occur between about 10 p.m. and 2 a.m., he recommends injecting at bedtime, without food for at least 45 minutes beforehand, and being asleep by around 10 [1]. He is firm on dose: ipamorelin "and most of these growth hormone released in peptide should be 100 micrograms" [1]. He has heard of anaphylaxis when people push to 200 to 400 micrograms chasing the warm flushing sensation [1].

"I think of these peptides as having flavors," he says [1]. In his telling:

• Ipamorelin is the cleanest and most specific for the growth hormone receptor but also the weakest; people lean out a little and sleep a little better, with few side effects [1].
• GHRP-6 is more potent but may also release prolactin and ACTH (driving cortisol) and triggers hunger, possibly disturbing sleep; that makes it the go-to for putting on mass or getting strong [1].
• MK-677 works orally with a similar profile. He took it once at bedtime and woke an hour later ravenously hungry: "don't take that one at bedtime. But it absolutely will stimulate your appetite" [1]. He says it can help older adults struggling to build muscle [1].
• Tesamorelin, at 2 milligrams per dose, is FDA-approved for visceral fat in HIV-related lipodystrophy and, in his experience, works better in women; he sees no appetite stimulation [1].
• Sermorelin has a broad dose range of 200 to 3,000 micrograms [1].
• Hexarelin, at 100 micrograms, is his morning "energy endurance" option: "It's not a caffeinated energy or jittery or anything like that," and he has not seen it spike appetite [1].

He used to combine ipamorelin, hexarelin or GHRP-6 with CJC-1295, which acts on growth hormone releasing hormone and helps the effect last longer, but at recording CJC-1295 had been removed: "the FDA just came in and let's just say one acronym took out another" [1]. His favorite stack combined BPC-157, ipamorelin and tesamorelin in one bedtime shot for fat loss, lean muscle, sleep, skin and thinking [1]. He sees growth hormone as a resiliency hormone for people who recover slowly from workouts, sprains or cuts, and applies the five-days-on, two-off schedule from traditional growth hormone dosing to peptides and even supplements, because "Anything you expose yourself to continually, doesn't work as well" [1].

Growth hormone peptides: Huberman's framework and warnings

Huberman's solo episode covers the same compounds but with a stronger emphasis on risk. Growth hormone output falls roughly 15% per decade after about age 30, reducing metabolism, fat loss, muscle growth and vitality [2]; in his metabolism episode he says nightly release drops two- to three-fold between ages 30 and 40 [3]. Synthetic growth hormone grows tissues indiscriminately, including any existing tumor, and shuts down the body's own production, which is why secretagogues were developed [2]. Too much growth hormone grows the heart, lungs, liver and spleen, not just muscle [3].

Because standard names are confusing, he sorts the peptides into two types [2]. Type one (sermorelin, tesamorelin, CJC-1295) mimics growth hormone releasing hormone and is the best tested in humans, with some FDA approvals [2]. He describes sermorelin doses of 200 to 400 micrograms before sleep, three to five times a week, since continuous daily use can cause some desensitization; tesamorelin (Egrifta) lasts longer and is typically taken about three times a week [2]. CJC-1295 lasts several days, but there was a death from cardiovascular dysfunction in one of its clinical trials and it can cause fluid retention, so he doesn't see why anyone would choose it until its safety issues are resolved [2].

Type two peptides raise growth hormone by mimicking ghrelin, the hunger peptide, which can also increase anxiety [2]. Ipamorelin also suppresses somatostatin and tends to deepen sleep, though whether that costs REM sleep is unknown [2]. Hexarelin produces the biggest growth hormone pulses, two to three times larger than the others, but can sharply raise prolactin, which may suppress libido and cause fluid retention and malaise, and, most concerning, it can desensitize growth hormone releasing hormone receptors, potentially shutting down the system's response to anything, including the body's own signals [2]. GHRP-2, -3 and -6 can raise prolactin and cortisol, with GHRP-3 more than doubling circulating cortisol, and MK-677 shares these issues [2].

He recounts his own experience. Sermorelin gave him great early-night sleep but wiped out his REM sleep later in the night, and "It spiked my prostate specific antigen. It was a very consistent effect. I came off it and it went back down and I went back on it went back up" [1]. Some people love sermorelin without these issues, he adds: "So it seems like it can be very individual" [1][2].

The risks he lists for raising growth hormone include, with growth hormone itself, carpal tunnel syndrome, changes in facial and body structure and unusual skin texture, which are less dramatic with peptides [2]. The major risk across all of them is increased tumor and cancer growth, and combining a growth hormone peptide with BPC-157 could increase both the size and blood supply of a tumor [2]. In his metabolism episode he adds that sermorelin can shut down your natural production of growth hormone releasing hormone: "Do they work? Yes. Do they shut down your natural production of growth hormone releasing hormone? Well, the answer is yes" [3]. Unlike the short spikes from exercise, arginine or sauna, repeated injections that keep levels constant can trigger long-lived changes in gene expression, and tumors grow when exposed to growth hormone [3]. He covered peptides there "not because I'm encouraging it, but because it is happening" [3].

Metabolism: GLP-1 microdosing

The metabolic side of the peptide story in these sources is mostly about GLP-1 drugs, which Huberman deliberately left out of his solo episode [2]. Dr. Koniver says the common complaint that GLP-1 users lose muscle usually reflects conventional doses that take weight off too fast, sometimes 15 pounds in three weeks, followed by rebound or the gaunt look known as Ozempic face [1]. His clinic uses compounded tirzepatide and semaglutide in micro doses, increased slowly, and in his experience people losing two pounds a week or less don't lose muscle, especially with adequate protein and resistance training [1]. His pharmacy now pairs tirzepatide with sermorelin to help offset muscle loss [1]. He has seen falling inflammation markers, including thyroid antibodies in a patient with Hashimoto's, and cognitive benefits, but he can't say whether these are direct effects or the result of losing fat [1]. His philosophy: "I like to help people win the race first" [1].

Sourcing: the risk everyone agrees on

Both episodes treat sourcing as a safety issue in its own right. Huberman describes three routes: prescription from a board-certified physician (via a pharmaceutical company or compounding pharmacy), the gray market online with questionable safety and efficacy, and the black market, where products are frequently contaminated or not what the label claims [2]. The key contaminant is lipopolysaccharide (LPS), an inflammatory toxin that can build up during manufacturing; a tiny amount may not cause much trouble, but repeated exposures can become a problem over time, and gray- and black-market products may contain the right compound without the LPS removed [2]. He worries about people buying peptides labeled "not for human or animal consumption, research purposes only" [1].

Dr. Koniver has seen the consequences: people who had anaphylactic reactions to research-grade peptides [1]. He contrasts these with compounding pharmacies, which are regulated by the FDA and state pharmacy boards, inspected regularly, and must have sterile products tested by outside labs for purity and endotoxins [1]. Huberman's line is unambiguous: "I implore you to do so with a board certified physician" [2].

Where They Agree, and Where They Don't

They agree that peptides are real, biologically active drugs with promise for healing and body composition, that clean pharmacy sourcing and an experienced physician are non-negotiable, that dosing should be conservative, and that cycling off matters [1][2]. Both accept that responses vary a lot between individuals, as Huberman's sermorelin experience shows [1][2]. And both acknowledge the evidence base is thin: the summary of Dr. Koniver's conversation notes it rests mostly on his years of clinical observation rather than published trials, which both men say openly [1].

They differ, sometimes sharply, on the details:

• Evidence. Dr. Koniver's confidence comes from thousands of patients he has watched improve [1]. Huberman's caution comes from the absence of controlled human trials, which means placebo effects can't be excluded [2]. Both are describing the same reality from different seats: a clinician sees patients get better; a scientist asks what would have happened without the drug.
• BPC-157 dosing. Dr. Koniver's clinic ran from 500 to as high as 5,000 micrograms a day, five days on and two off [1]. Huberman describes 300 to 500 micrograms two or three times a week for about eight weeks, then eight to ten weeks off, and thinks daily, indefinite use is a bad idea [2].
• Side effects of BPC-157. Dr. Koniver reports none of note [1]. Huberman flags a theoretical but serious tumor risk through VEGF and angiogenesis [2]. These aren't necessarily contradictory: a tumor risk would not show up as a side effect patients notice.
• Stacking BPC-157 with growth hormone peptides. Dr. Koniver sees BPC-157's growth hormone receptor effect as a benefit that allows lower peptide doses, and his favorite stack combines them [1]. Huberman sees the same combination as a possible way to increase both the size and blood supply of a tumor [2].
• Hexarelin. Dr. Koniver likes it as a clean morning energy peptide without appetite effects [1]. Huberman warns it can sharply raise prolactin and desensitize growth hormone releasing hormone receptors [2].
• CJC-1295. Dr. Koniver used it classically alongside ipamorelin and others [1]. Huberman cites a death from cardiovascular dysfunction in one of its trials and sees no reason to choose it until that is resolved [2].
• Ipamorelin. Dr. Koniver describes "no real side effects" [1]. Huberman groups it with the ghrelin mimetics and says whether its deeper sleep comes at the expense of REM is unknown [2].
• Feedback shutdown. The core pitch for peptides is that they avoid the shutdown of natural production that hormones cause [1]. Huberman agrees they are gentler than growth hormone, but says sermorelin can still shut down natural growth hormone releasing hormone production [3], and that hexarelin may desensitize the system [2].
• Meal timing. Dr. Koniver asks for no food for at least 45 minutes before a bedtime dose [1]. Huberman describes taking these peptides at least an hour and a half to two hours after eating, with no food for 30 minutes afterward [2], and notes that eating within two hours of sleep suppresses natural growth hormone release [3].

On regulation, Dr. Koniver thinks the FDA's removals are "probably both: good intentions to regulate a wild, wild west" plus overreach, alongside drug companies that may want to turn popular peptides into expensive branded drugs [1]. Huberman's solo episode doesn't weigh in on motives, but his account of gray-market contamination shows why regulators see a wild west [2].

Why It Works

Pleiotropy is both the power and the risk. Huberman calls this the single most important concept: when a peptide binds its receptor, it sets off a "bucket brigade" of downstream processes, perhaps growth in one pathway, cell migration in another and blood vessel growth in a third [2]. A peptide may do anywhere from four to a thousand things, so anyone taking one for a specific purpose will activate other pathways too, which shapes effects, side effects, dosing and cycling [2].

Healing peptides work by building supply lines. BPC-157 grows new blood vessels and draws in fibroblasts to scaffold the repair [2]. Thymosin beta-4 drives stem cell proliferation and extracellular matrix growth [2]. The same blood supply that feeds a healing tendon can feed a tumor, which is why VEGF-blocking drugs like Avastin are used against cancer [2].

Growth hormone peptides pull on the body's own cascade. The hypothalamus releases growth hormone releasing hormone, the pituitary releases growth hormone, and the liver makes IGF-1 [1][2][3]. Type one peptides mimic the hypothalamic signal; type two mimic ghrelin [2]. Because release happens mostly in deep early-night sleep when blood sugar and insulin are low, dosing is timed for bedtime on an empty stomach [1][2][3]. Growth hormone raises ATP production and helps the body burn fat and build muscle, bone and cartilage [2][3].

Side effects follow from the pathways. Ghrelin mimetics raise hunger and sometimes anxiety [2]. Some peptides spill over into prolactin and ACTH, and therefore cortisol [1][2]. Constant stimulation, unlike natural short pulses, can desensitize receptors or change gene expression over the long term [2][3].

Behavior already moves the same dial. Huberman notes that exercise of up to about 60 minutes with a real warm-up and pushing close to failure raised growth hormone 300 to 500 percent, plus a similar increase the following night [3]. Arginine can raise it 400 to 600 percent, though "this is definitely a case of more is not better" above 9 grams, and it does not stack with exercise [3]. Sauna sessions raised growth hormone up to 16-fold in a study of 17 people, with a stark warning: "proceed with extreme caution," because overheating can permanently damage neurons [3]. He finds it encouraging that with sleep, exercise and not eating before bed, "we're in a position to actually offset the age related decline in growth hormone completely just through behaviors" [3].

Where It Applies, and Where It Doesn't

The strongest case, by the sources' own accounts, is for tendon, ligament and joint injuries and gut inflammation (BPC-157 and its substitute), and for older adults who recover slowly, have lost muscle or carry visceral fat (growth hormone peptides such as tesamorelin, which has FDA approval for visceral fat in HIV) [1][2]. The type one secretagogues, sermorelin and tesamorelin, have the most human data [2].

The weakest case is for young, healthy people. Huberman doesn't see why anyone under 30 would augment growth hormone without a clinical need [2]. The broader warning from Dr. Koniver's testosterone story applies in spirit: a 25-year-old who used testosterone and growth hormone from his late teens felt like "Superman," then found he had zero sperm when he wanted children [1].

Peptides are riskiest for anyone with a known cancer, a history or suspicion of tumors, or eye diseases involving vascular overgrowth [2]. Anyone with melanoma should be very cautious with peptides that stimulate melanocytes, such as melanotan and PT-141 [2]. Longevity claims are weaker still: epitalon's evidence is largely animal studies, and Huberman calls using it to extend human life "a leap" [2].

The legal ground is also shifting. BPC-157 has been barred from compounding since October 2023, several peptides have come and gone, and a few were allowed again just before one episode was released [1]. What your doctor can legally prescribe may differ from what you read online.

What To Do With It

1. Try the free levers first. Protect deep early-night sleep, stop eating about two hours before bed, and train for up to about an hour with a real warm-up, pushing near failure and cooling down promptly afterward. Huberman reports these can raise growth hormone several-fold without injections [3].
2. If you pursue peptides, do it with a board-certified physician experienced in them. Both men insist on it, not least because responses vary so much between individuals [1][2]. Medical advice is especially important here; these are drugs, not supplements.
3. Never use "research purposes only" products. Get peptides from a compounding pharmacy or a pharmaceutical company, whose products are tested for purity and endotoxins; gray-market products risk LPS contamination and have caused anaphylaxis [1][2].
4. Screen for tumors before growth-promoting peptides, especially if you're over 30 or have any cancer history, and keep monitoring with regular blood work [2]. Be wary of stacking BPC-157 with growth hormone peptides if tumor risk is a concern [2].
5. Use the minimum effective dose and respect ceilings. Dr. Koniver caps ipamorelin-type peptides at 100 micrograms, and has heard of anaphylaxis at 200 to 400 [1]; Huberman describes BPC-157 at 300 to 500 micrograms, two or three times a week [2].
6. Cycle off. Dr. Koniver uses five days on and two off [1]; Huberman suggests around eight weeks of BPC-157 followed by eight to ten weeks off, and warns against daily, indefinite use [2].
7. Time growth hormone peptides for bedtime on an empty stomach. Aim for no food for at least 45 minutes (Dr. Koniver) to two hours (Huberman) beforehand and avoid eating for about 30 minutes afterward [1][2]. Don't take appetite-driving ones like MK-677 right before bed [1].
8. Prefer the better-studied, milder options. Huberman favors the type one peptides, sermorelin and tesamorelin, and would avoid CJC-1295 until its safety question is resolved [2].
9. Track your own response. Huberman caught the REM loss and PSA rise from sermorelin by watching his sleep trackers and lab results, and confirmed the pattern by coming off and going back on [1][2]. Stop if the numbers move the wrong way.
10. Treat the hype with healthy skepticism. With one poor human study behind a peptide millions use, some of what people feel may be placebo [2]. As Huberman puts it, "I'm not here to tell you what to do or what not to do," but you should go in informed [2].

Sources

1. Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity · Huberman Lab
2. Benefits & Risks of Peptide Therapeutics for Physical & Mental Health · Huberman Lab
3. How to Control Your Metabolism by Thyroid & Growth Hormone · Huberman Lab